Illumina (ILMN) Strategy Update summary

Strategic vision and growth outlook

• Aims to accelerate revenue growth to high single digits by 2027, driven by core sequencing, multi-omics expansion, and expanded services and software offerings.

• Focuses on transitioning customers to NovaSeq X, expanding into multi-omics, and operational excellence for margin and EPS growth.

• Emphasizes shifting from cost per gigabase to delivering high-quality insights at the lowest end-to-end workflow cost.

• Multi-omics and AI-powered data analysis are central to future growth and customer value.

• Customer-centric approach targets research, clinical, and pharma segments with tailored solutions.

Market opportunity and customer segments

• NGS currently serves only a fraction of the $125B addressable market, with clinical and research markets growing at 18% and 6% CAGRs, respectively.

• Largest global installed base with over 21,600 active instruments, supporting a highly diversified revenue profile.

• Strategic partnerships, such as with Broad Institute, aim to catalyze adoption of high-capacity single cell experiments.

• Multi-omics and single-cell applications expected to drive higher sequencing intensity and revenue per sample.

• Serves research, pharma, and clinical segments, each reinforcing the other and expanding the customer base.

Innovation and product roadmap

• NovaSeq X Series is the fastest-growing high-throughput sequencer, with 469 units installed and ~45% of high-throughput output attributed to it.

• Upcoming launches include the 5-base genome and comprehensive genome, offering combined variant and epigenetic data in simplified workflows.

• Acquisitions of Partek and Fluent BioSciences expand capabilities in single-cell and multi-omics workflows.

• Integrated platforms like Partek streamline multi-omic analysis, leveraging AI for actionable insights.

• Ongoing R&D investments focus on expanding biological content, workflow simplification, and accelerating software and AI development.